Highly selective aldose reductase inhibitors. 3. Structural diversity of 3-(arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic acids

Journal of Medicinal Chemistry

Volumn 40, Issue 5, 1997, Pages 684-694

  Kotani, Takayuki ^a   Nagaki, Yasuhiro ^a   Ishii, Akira ^a   Konishi, Yukari ^a   Yago, Hisashi ^a   Suehiro, Seishi ^a   Okukado, Nobuhisa ^a   Okamoto, Kaoru ^a  

^a Nippon Zoki Pharmaceutical Co   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(5 CHLOROBENZOTHIAZOL 2 YL)METHYL] 1,2,3,4 TETRAHYDRO 2,4 DIOXOPYRIMIDINE 1 ACETIC ACID; ALDOSE REDUCTASE INHIBITOR; ALRESTATIN; EPALRESTAT; PONALRESTAT; TOLRESTAT; UNCLASSIFIED DRUG; ZENARESTAT; ZOPOLRESTAT;

ARTICLE; DIABETIC COMA; DRUG ACCUMULATION; ENZYME INHIBITION; GLYCATION; HYDROPHOBICITY; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACETIC ACIDS; ALDEHYDE REDUCTASE; ANIMALS; BENZOTHIAZOLES; DIABETES COMPLICATIONS; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; KIDNEY; LENS, CRYSTALLINE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHTHALAZINES; PYRIMIDINONES; RATS; SORBITOL; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 0031058373     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960594+     Document Type: Article

References (34)

1. Kador, P. F. The role of Aldose Reductase in the Development of Diabetic Complications. Med. Res. Rev. 1988, 8, 325-352.
2. Kador, P. F.; Kinoshita, J. H.; Sharpless, N. E. Aldose Reductase Inhibitors: A Potential New Class of Agents for the Pharmacological Control of Certain Diabetic Complications. J. Med. Chem. 1985, 28, 841-849.
3. Kador, P. F.; Robinson, W. G.; Kinoshita, J. H. The Pharmacology of Aldose Reductase Inhibitors. Annu. Rev. Pharmacol. Toxicol. 1985, 25, 691-714.
4. Tanimoto, T.; Nishimura, C. Biochemistry and Clinical Significance of Aldose Reductase. Peripheral Nerve 1993, 4, 149-158.
5. Dvornik, D. In Aldose Reductase Inhibition: An Approach to the Prevention of Diabetic Complications; Porte, D., Ed.; McGraw-Hill: New York, 1987; Chapter 4.
6. Mylari, B. L.; Larson, E. R.; Beyer, T. A.; Zembrowski, W. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Singleton, D. H. Novel, Potent Aldose Reductase Inhibitors: 3,4-Dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]-methyl]-1- phthalazineacetic Acid (Zopolrestat) and Congeners. J. Med. Chem. 1991, 34, 108-122.
7. Yamagishi, M.; Yamada, Y.; Ozaki, K.; Asao, M.; Shimizu, R.; Suzuki, M.; Matsumoto, M.; Matsuoka, Y.; Matsumoto, K. Biological Activities and Quantitative Structure-Activity Relationships of Spiro[imidazolidine-4,4′(1′H)-quinazoline]-2,2′,5-(3′H)- triones as Aldose Reductase. J. Med. Chem. 1992, 35, 2085-2094.
8. Wrobel, J.; Millen, J.; Sredy, J.; Dietrich, A.; Gorham, B. J.; Malamas, M.; Kelly, J. M.; Bauman, J. G.; Harrison, M. C.; Jones, L. R.; Guinosso, C.; Sestanj, K. Syntheses of Tolrestat Analogues Containing Additional Substituents in the Ring and Their Evaluation as Aldose Reductase Inhibitors. Identification of Potent, Orally Active 2-Fluoro Derivatives. J. Med. Chem. 1991, 34, 2504-2520.
9. Billon, F.; Delchambre, C.; Cloarec, A.; Sartori, E.; Teulone, J.-M. Aldose Reductase Inhibition by 2,4-Oxo and Thioxo Derivatives of 1,2,3,4-Tetrahydroquinazoline. Eur. J. Med. Chem. 1990, 25, 121-126.
10. Matsui, T.; Nakamura, Y.; Ishikawa, H.; Matsuura, M.; Kobayashi, F. Pharmacological Profiles of a Novel Aldose Reductase Inhibitor, SPR-210, and Its Effects on Streptozotocin-Induced Diabetic Rats. Jpn. J. Pharmacol. 1994, 64, 115-124.
11. Mylan, B. L.; Beyer, T. A.; Siegel, T. W. A Highly Specific Aldose Reductase Inhibitor, Ethyl 1-Benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and Its Congeners. J. Med. Chem. 1991, 34, 1011-1018.
12. Smar, M. W.; Ares, J. J.; Nakayama, T.; Itabe, H.; Kador, P. F.; Miller, D. D. Selective Irreversible Inhibitors of Aldose Reductase. J. Med. Chem. 1992, 35, 1117-1120.
13. Srivastava, S. K.; Petrash, J. M.; Sadana, I. J.; Ansari, N. H.; Partridge, C. A. Susceptibility of Aldehyde and Aldose Reductases of Human Tissues to Aldose Reductase Inhibitors. Curr. Eye Res. 1982, 2, 407-410.
14. Sato, S.; Kador, P. F. Inhibition of Aldehyde Reductase by Aldose Reductase Inhibitors. Biochem. Pharmacol. 1990, 40, 1033-1042.
15. Poulsom, R. Inhibition of Hexonate Dehydrogenase and Aldose Reductase from Bovine Retina by Solbinil, Statil, M79175 and Valproate. Biochem. Pharmacol. 1986, 35, 2955-2959.
16. Terubayashi, H.; Sato, S.; Nishimura, C.; Kador, P. F.; Kinoshita, J. H. Localization of Aldose and Aldehyde Reductase in the Kidney. Kidney Int. 1989, 36, 843-851.
17. Tanimoto, T.; Nishiyama, C. Molecular Biology of Aldose Reductase. Exp. Med. 1991, 9, 541-547.
18. Hotta, N.; Sakamoto, N. Polyol Pathway and Diabetic Complications. Metab. Disease 1989, 26, 621-632.
19. Tanimoto, T.; Nishimura, C. Molecular Structure and Function of Aldose Reductase. J. Clin. Exp. Med. (Igaku No Ayumi) 1991, 156, 998-1002.
20. Feather, M. S.; Flynn, T. G.; Munro, K. A.; Kubiseski, T. J.; Walton, D. J. Catalysis of Reduction of Carbohydrate 2-Oxoaldehyde (osones) by Mammalian Aldose Reductase and Aldehyde Reductase. Biochim. Biophys. Acta 1993, 1244, 10-16.
21. Ratliff, D. M.; Jagt, D. J. V.; Eaton, R. P.; Jagt, D. L. V. Increase Levels on Methylglyoxal-Metabolizing Enzymes in Mononuclear and Polymorphonuclear Cells from Insulin-Dependent Diabetic Patients with Diabetic Complications: Aldose Reductase, Glyoxalase I, and Glyoxalase II - A Clinical Research Center Study. J. Clin. Endocrinol. Metab. 1996, 87, 488-492.
22. Ishii, A.; Kotani, T.; Nagaki, Y.; Shibayama, Y.; Toyomaki, Y.; Okukado, N.; Ienaga, K.; Okamoto, K. Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids. J. Med. Chem. 1996, 39, 1924-1927.
23. Kotani, T.; Ishii, A.; Nagaki, Y.; Toyomaki, Y.; Yago, H.; Suehiro, S.; Okukado, N.; Okamoto, K. Highly Selective Aldose Reductase Inhibitors. 2. Optimization of the Aryl part of 3-(Arylmethyl)-2,4,5-trioxoimidazolidine-1-acetic Acids. Chem. Pharm. Bull. 1996, in press.
24. Lee, Y. S.; Pearlstein, R.; Kador, P. F. Molecular Modeling Studies of Aldose Reductase Inhibitors. J. Med. Chem. 1994, 37, 787-792.
25. Kador, P. F.; Sharpless, N. E. Pharmacophore Requirements of the Aldose reductase Inhibitor Site. Mol. Pharmacol. 1983, 24, 521-531.
26. Pechmann, V.; Ansel. Chem. Ber. 1990, 33, 618.
27. Cava, M. P.; Levinson, M. I. Thionation Reactions with Lawesson's Reagents. Tetrahedron 1985, 41, 5061-5087.
28. Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1-28.
29. Baker, B. R.; Schwan, T. J. Nonclassical Antimetabolites. XXVI. Inhibitors of Thymidine Kinase. II. Inhibition by Functionalized 1-Alkyluracils. J. Med. Chem. 1966, 9, 73-76.
30. Kador, P. F.; Kinoshita, J. H.; Brittain, D. R.; Mirrlees, D. J.; Sennitt, C. M.; Stribling, D. Purified Rat Lens Aldose Reductase. Polyol Production in vitro and its Inhibition by Aldose Reductase Inhibitors. Biochem. J. 1986, 240, 233-237.
31. Takahashi, N.; Saito, T.; Tomita, K. Purification and Properties of an NADPH-linked Aldehyde Reductase from Rat Kidney. Biochim. Biophys. Acta 1983, 748, 444-452.
32. Petrash, J. M.; Tarle, I.; Wilson, D. K.; Quiocho, F. A. Aldose Reductase Catalysis and Crystallography. Insights From Recent Advances in Enzyme Structure and Function. Diabetes 1994, 43, 955-595.
33. Ichikawa, H. PSDD (Perceptron-type Neural Network Simulator). JCPE P054. Aoyama, T.; Ichikawa, H. Reconstruction of Weight Matrices in Neural Networks - A Method of Correlating Outputs with Inputs. Chem. Pharm. Bull. 1991, 39, 1222-1228 and references cited therein.
34. Wilson, D. K.; Tarle, I.; Petrash, J. M.; Quiocho, F. A. Refined 1.8 Å Structure of Aldose Reductase Complexed with the Potent Inhibitor Zopolrestat. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9847-9851.